Colchicine in Moderate Symptomatic COVID-19 Patients (COLCOVIDBD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04527562 |
Recruitment Status :
Completed
First Posted : August 26, 2020
Last Update Posted : January 11, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Covid19 | Drug: Colchicine Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 299 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy |
Actual Study Start Date : | July 14, 2020 |
Actual Primary Completion Date : | November 15, 2020 |
Actual Study Completion Date : | December 10, 2020 |

Arm | Intervention/treatment |
---|---|
Active Comparator: TRAETMENT GROUP
Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
|
Drug: Colchicine
Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given. |
Placebo Comparator: CONTROL /PLACEBO GROUP
COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo. Standard care of enrolled study patients will consist:
|
Drug: Placebo
Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given. |
- Time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a Seven-category ordinal scale. [ Time Frame: 14 days following randomization ]Seven-category ordinal scale. The scale is recommended by the WHO R&D Blueprint expert group. The seven-category ordinal scale consisted of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and 7, death
- Length of hospital stay [ Time Frame: 14 days following randomization ]Days from date of enrollment to date of discharge
- Number of participant requiring increased amount of supplemental oxygen [ Time Frame: 14 days following randomization ]Proportion of participants who required oxygen supplementation
- Number of participants requiring mechanical ventilation [ Time Frame: 14 days following randomization ]Proportion of participants who required mechanical ventilation
- Number of participants who die [ Time Frame: 14 days following randomization ]Proportion of participants who die from any cause

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Males and females of least 18 years of age and can swallow tablets
- Competent and willing to provide informed consent
- Patient must have received a diagnosis of COVID-19 infection with positive RT-PCR for SARS CoV-2 within the last 3 days
-
Patients with moderate symptoms (According to National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID- 19).Version 7.0 .2020, DGHS, MOHFW, Government of the People's Republic of Bangladesh). Following features of moderate covid-19 must be present-
- Fever or history of fever
- Cough and /or Shortness of breath
- Oxygen saturation 94% or more
- Pneumonia -pulmonary consolidations on chest imaging (chest x ray or CT scan of chest) involving less than 50%of lungs
- CRB 65 score 0
Exclusion criteria:
- Pregnancy and breast-feeding
- Known hypersensitivity to colchicine
- Known chronic illness e.g hepatic failure, chronic kidney disease (eGFR<30ml/min), decompensated heart failure, long QT syndrome (QTc >450 msec.)
- Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption
- Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout)
- Patient undergoing chemotherapy for cancer
- Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04527562
Bangladesh | |
Dhaka Medical College Hospital | |
Dhaka-1000, Bangladesh |
Study Chair: | Mujibur Rahman, MBBS,MD,FCPS | Professor and Head, Department of Medicine | |
Principal Investigator: | Motlabur Rahman, MBBS, FCPS,FACP | Associate Professor, Department of Medicine |
Responsible Party: | Dr. Md. Motlabur Rahman, Associate Professor, Department of Medicine, Dhaka Medical College |
ClinicalTrials.gov Identifier: | NCT04527562 |
Other Study ID Numbers: |
U1111-1255-3541 |
First Posted: | August 26, 2020 Key Record Dates |
Last Update Posted: | January 11, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Covid 19 Colchicine |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections |
Lung Diseases Respiratory Tract Diseases Colchicine Gout Suppressants Antirheumatic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |